NCT06344351View on ClinicalTrials.gov

A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions
Advanced Malignant Neoplasm
Interventions
DRUG

TQB3006 tablets

TQB3006 is an inhibitor protein.

Trial Locations (5)

100144

Peking University Shougang Hospital, Beijing

150000

Harbin Medical University Cancer Hospital, Harbin

230000

Anhui Provincial Hospital, Hefei

400015

Chongqing university Cancer Hospital, Chongqing

450003

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY